avapro has been researched along with Liver Diseases in 3 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based on these pharmacokinetic and safety data, no dosage adjustments of IRBE are necessary for patients with RI, HI, or HF, or based on patient age, gender, or race." | 2.41 | Pharmacokinetics of irbesartan are not altered in special populations. ( Marino, MR; Vachharajani, NN, 2002) |
| " Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h)." | 2.40 | The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ( Brunner, HR, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, MA | 1 |
| Amin, EF | 1 |
| Ibrahim, SA | 1 |
| Abdelzaher, WY | 1 |
| Abdelrahman, AM | 1 |
| Brunner, HR | 1 |
| Marino, MR | 1 |
| Vachharajani, NN | 1 |
2 reviews available for avapro and Liver Diseases
| Article | Year |
|---|---|
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Interactions; Hu | 1997 |
Pharmacokinetics of irbesartan are not altered in special populations.
Topics: Adolescent; Adult; Aged; Biphenyl Compounds; Child; Female; Heart Failure; Humans; Hypertension; Irb | 2002 |
1 other study available for avapro and Liver Diseases
| Article | Year |
|---|---|
Montelukast and irbesartan ameliorate metabolic and hepatic disorders in fructose-induced metabolic syndrome in rats.
Topics: Acetates; Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds | 2014 |